Goetz Partners was pleased with the news and reiterated its outperform rating and 90 cents price target this morning.It commented: “With Immutep’s Eftilagimod alpha (efti) also showing positive benefits in combination with PD-1 in HNSCC (head and neck cancer) and non-small cell lung cancer (NSCLC), these new data highlight the potential of Immutep’s in-house and partnered programme. With the prospect of further HNSCC and NSCLC data from TACTI-002, final AIPAC survival data expected over the course of 2021E, we reiterate our OUTPERFORM recommendation and AUD$0.9 target price.”This price target implies potential upside of ~100% for the Immutep share price over the next 12 months.
90 cents is the price target
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.025(7.04%) |
Mkt cap ! $479.3M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 32.5¢ | $907.7K | 2.704M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 156372 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 78798 | 11 |
View Market Depth
| Last trade - 10.55am 15/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |